Unknown

Dataset Information

0

Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.


ABSTRACT: There has been an exponential growth in the performance and output of sequencing technologies (omics data) with full genome sequencing now producing gigabases of reads on a daily basis. These data may hold the promise of personalized medicine, leading to routinely available sequencing tests that can guide patient treatment decisions. In the era of high-throughput sequencing (HTS), computational considerations, data governance and clinical translation are the greatest rate-limiting steps. To ensure that the analysis, management and interpretation of such extensive omics data is exploited to its full potential, key factors, including sample sourcing, technology selection and computational expertise and resources, need to be considered, leading to an integrated set of high-performance tools and systems. This article provides an up-to-date overview of the evolution of HTS and the accompanying tools, infrastructure and data management approaches that are emerging in this space, which, if used within in a multidisciplinary context, may ultimately facilitate the development of personalized medicine.

SUBMITTER: Lightbody G 

PROVIDER: S-EPMC6917217 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.

Lightbody Gaye G   Haberland Valeriia V   Browne Fiona F   Taggart Laura L   Zheng Huiru H   Parkes Eileen E   Blayney Jaine K JK  

Briefings in bioinformatics 20190901 5


There has been an exponential growth in the performance and output of sequencing technologies (omics data) with full genome sequencing now producing gigabases of reads on a daily basis. These data may hold the promise of personalized medicine, leading to routinely available sequencing tests that can guide patient treatment decisions. In the era of high-throughput sequencing (HTS), computational considerations, data governance and clinical translation are the greatest rate-limiting steps. To ensu  ...[more]

Similar Datasets

| S-EPMC3062900 | biostudies-literature
| S-EPMC8392551 | biostudies-literature
| S-EPMC9444142 | biostudies-literature
| S-EPMC3565686 | biostudies-literature
| S-EPMC4598076 | biostudies-other
| S-EPMC6112240 | biostudies-literature
| S-EPMC4891951 | biostudies-literature
| S-EPMC3495985 | biostudies-literature
| S-EPMC6858616 | biostudies-literature
| S-EPMC9965772 | biostudies-literature